RESMED INC

ResMed’s fiscal 2027 outlook drops $75 M from its Astral ventilator recall, citing supply‑chain strain and freight cost hikes that squeeze margins and shake investor confidence.

ResMed’s FY‑2026 results: $3.18B revenue, 22% margin, and a 10% dividend hike—boosting sleep‑therapy growth and digital health while navigating recalls and new competition.

ResMed’s Class I recall of Astral 100 and 150 ventilators—due to leaking super‑capacitors—details repairs, safety steps, and impact on care.

ResMed Inc. defends steady earnings and cash flow amid market volatility, while its AI‑driven sleep‑health tech positions it for growth in value‑based care.

ResMed (RMD) soars on low‑rate Aussie markets, strong sleep‑apnea pipeline and global diversification – a compelling growth play for long‑term investors.

Katana Capital’s July 2026 update highlights resilient NTA, a strategic tech‑health focus, and ResMed’s inclusion, underscoring its risk‑managed growth strategy.

Australian Foundation Investment Company (AFI) boosts NTA, $9.8B portfolio, top holdings BHP, CBA, Macquarie—low 0.16% fee and long‑term equity focus.

Perennial ETF spots ResMed as a top health‑tech pick, noting its strong EBITDA growth, ESG focus, and growing reimbursement pathways that boost ROI for patients and investors.

ResMed’s recent 4 % share dip amid market volatility is offset by strong regulatory wins, robust safety data, and a 15 % efficacy boost from its new cloud‑based digital platform.

Investors learn how ResMed’s insider sales signal risk and strategy—tax, governance, and market moves—impacting shareholder value in the competitive sleep‑care sector.